Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.
Latest News

Did Danaher’s (DHR) New AI-Powered Autonomous Lab at Abcam Just Redefine Its Innovation Edge?

Danaher (DHR) Stock May Be 4% Undervalued Despite AI Lab Launch

Is Danaher (DHR) Undervalued As Its New AI Lab Pushes Faster Antibody Development?

Danaher (DHR) Launched Its First AI Powered Autonomous Laboratory
Baird Adjusts Price Target on Danaher to $246 From $238

Top Stock Reports for AMD, Palo Alto & ConocoPhillips
Related stocks
Key Metrics & Overview
Detailed metrics & financial data of the company
🛡️ Risk & Structural Analysis
Multi-Factor Risk Model & Market Data